KLOW
Also known as: KLOW Protocol, KLOW Blend, KPV+BPC-157+TB-500+GHK-Cu
KLOW is a four-peptide research blend specifically engineered for comprehensive tissue repair and inflammation control. Each component targets a distinct but complementary biological pathway: GHK-Cu drives collagen gene expression and skin/tissue remodeling; KPV suppresses NF-κB-driven inflammation; BPC-157 promotes angiogenesis and gut/tendon healing; TB-500 enables cell migration and systemic repair. Together, they address recovery from multiple angles simultaneously.
Regulatory & Approval Status
KLOW is a research-only compound and is not an FDA-approved therapeutic agent; there is no evidence of clinical trial progression for this specific designation.
Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.